Tiwari Avinash, Ghoshal Arun, Deodhar Jayita K, Muckaden Mary Ann
Department of Palliative Medicine and Supportive Care, Sanjeevani CBCC USA Cancer Hospital, Raipur, Chhattisgarh, India.
Department of Palliative Medicine and Supportive Care, Kasturba Medical College and Hospital, Manipal, Karnataka, India.
Indian J Palliat Care. 2024 Oct-Dec;30(4):353-357. doi: 10.25259/IJPC_104_2024. Epub 2024 Nov 15.
In this study, our primary objectives were to validate the palliative prognostic index (PPI) tool in the context of palliative care for patients with advanced cancer. Specifically, we aimed to assess the accuracy of the PPI in predicting actual survival in these patients through prospective validation.
To achieve our objectives, we enrolled a cohort of 227 advanced cancer patients receiving palliative care. The study population comprised 132 (58.1%) men and 95 (41.9%) women, with a median age of 52 years (Range: 20-81). Among them, 56 (24.7%) underwent chemotherapy, and 26 (11.5%) underwent palliative radiotherapy. We utilised the PPI score to categorise patients into three prognostic groups: (a) PPI score <4 indicating likely survival of more than 6 weeks; (b) PPI score 4-6 indicating likely survival shorter than 6 weeks; and (c) PPI score >6 indicating likely survival <3 weeks.
Through our analysis, we found that the PPI demonstrated limited predictive capabilities, particularly for short-term survival (<3 weeks). The PPI's performance metrics included a positive predictive value of 45.24%, a negative predictive value of 100%, a sensitivity of 100.00% and a specificity of 88.94%.
In conclusion, our study establishes the limited reliability of the PPI in predicting short-term survival (<3 weeks) among patients in palliative care with advanced cancer. These findings underscore the PPI's potential as a valuable tool for healthcare professionals, aiding in the development of treatment plans and facilitating discussions on end-of-life care options with patients and their families. In addition, the PPI may assist healthcare professionals in identifying individuals who could benefit from more aggressive interventions or those approaching the end of life, thereby guiding the provision of additional support and care.
在本研究中,我们的主要目的是在晚期癌症患者的姑息治疗背景下验证姑息预后指数(PPI)工具。具体而言,我们旨在通过前瞻性验证评估PPI在预测这些患者实际生存情况方面的准确性。
为实现我们的目标,我们招募了一组227名接受姑息治疗的晚期癌症患者。研究人群包括132名(58.1%)男性和95名(41.9%)女性,中位年龄为52岁(范围:20 - 81岁)。其中,56名(24.7%)接受了化疗,26名(11.5%)接受了姑息性放疗。我们利用PPI评分将患者分为三个预后组:(a)PPI评分<4表明可能生存超过6周;(b)PPI评分4 - 6表明可能生存短于6周;(c)PPI评分>6表明可能生存<3周。
通过我们的分析,我们发现PPI的预测能力有限,尤其是对于短期生存(<3周)。PPI的性能指标包括阳性预测值为45.24%,阴性预测值为100%,敏感性为100.00%,特异性为88.94%。
总之,我们的研究证实了PPI在预测晚期癌症姑息治疗患者短期生存(<3周)方面的可靠性有限。这些发现强调了PPI作为医疗保健专业人员的宝贵工具的潜力,有助于制定治疗计划,并促进与患者及其家属就临终护理选择进行讨论。此外,PPI可能有助于医疗保健专业人员识别那些可能从更积极的干预中受益的个体或那些接近生命末期的个体,从而指导提供额外的支持和护理。